Milestone Pharmaceuticals
Milestone is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone’s lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrial arrhythmias and angina.
Our partnership
Milestone Pharma is a BDC Capital Healthcare Venture Fund company, co-managed in partnership by Amplitude Venture Capital.
Contact
Dion Madsen, Founding partner at Amplitude Venture Capital.
Recent news
Milestone Pharmaceuticals Closes $55 Million Series C Financing
Learn MoreMilestone Pharmaceuticals Closes US$17 Million Series B Financing to Complete Phase 2 Clinical Studies for MSP-2017
Learn MoreMilestone Pharmaceuticals Announces USAN Approval of Generic Name "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia
Learn MoreCertain news link to external sites and are presented in French only.